当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
Hydromorphone HCl
HUMAN COMPOUNDED DRUG
71266-9110
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
HYDROMORPHONE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.2 mg/1 mL
71266-9110-3
Mitomycin 0.2mg/mL
HUMAN COMPOUNDED DRUG
71266-8475
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
MITOMYCIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.2 mg/1 mL
71266-8475-3
Mitomycin Bladder Instillation
HUMAN COMPOUNDED DRUG
71266-6412
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
MITOMYCIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.5 mg/1 mL
71266-6412-3
Ketamine HCl
HUMAN COMPOUNDED DRUG
71300-6616
Nubratori Inc.
2024-2
KETAMINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
50 mg/1 g
71300-6616-2
Lidocaine
HUMAN COMPOUNDED DRUG
71300-6676
Nubratori Inc.
2024-2
LIDOCAINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
75 mg/1 g
71300-6676-2
Lidocaine
HUMAN COMPOUNDED DRUG
71300-6726
Nubratori Inc.
2024-2
LIDOCAINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
75 mg/1 g
71300-6726-2
S-E012.5
HUMAN COMPOUNDED DRUG
79559-3012
F. H. Investments. Inc. DBA Asteria Health
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
12.5 mg/12.5 mg
79559-3012-1
S-E025
HUMAN COMPOUNDED DRUG
79559-3025
F. H. Investments. Inc. DBA Asteria Health
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
25 mg/25 mg
79559-3025-1
S-T200
HUMAN COMPOUNDED DRUG
79559-1200
F. H. Investments. Inc. DBA Asteria Health
2024-2
TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
200 mg/200 mg
79559-1200-1
S-T025
HUMAN COMPOUNDED DRUG
79559-1025
F. H. Investments. Inc. DBA Asteria Health
2024-2
TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
25 mg/25 mg
79559-1025-1
S-T012.5
HUMAN COMPOUNDED DRUG
79559-1012
F. H. Investments. Inc. DBA Asteria Health
2024-2
TESTOSTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
12.5 mg/12.5 mg
79559-1012-1
S-E010
HUMAN COMPOUNDED DRUG
79559-3010
F. H. Investments. Inc. DBA Asteria Health
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/10 mg
79559-3010-1
S-E006
HUMAN COMPOUNDED DRUG
79559-3006
F. H. Investments. Inc. DBA Asteria Health
2024-2
ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
6 mg/6 mg
79559-3006-1
141063 HYDROQUINONE 6% / TRETINOIN 0.05% / TRIAMCINOLONE ACETONIDE 0.025%
HUMAN COMPOUNDED DRUG
72934-6389
SKNV
2024-2
TRIAMCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.025 g/100 mL; 6 g/100 mL; .05 g/100 mL
72934-6389-2
021023 IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / NIACINAMIDE 2% Gel
HUMAN COMPOUNDED DRUG
72934-1341
SKNV
2024-2
NIACINAMIDE; LEVOCETIRIZINE DIHYDROCHLORIDE; IMIQUIMOD
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 g/100 mL; 1 g/100 mL; 5 g/100 mL
72934-1341-2
011550 DAPSONE 6% / NIACINAMIDE 4% Cream
HUMAN COMPOUNDED DRUG
72934-2321
SKNV
2024-2
NIACINAMIDE; DAPSONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; 6 g/100 mL
72934-2321-2
031070 TACROLIMUS 0.1%
HUMAN COMPOUNDED DRUG
72934-4349
SKNV
2024-2
TACROLIMUS
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.1 g/100 mL
72934-4349-8
071040 CICLOPIROX 8% / FLUCONAZOLE 1% / TERBINAFINE HCL 1%
HUMAN COMPOUNDED DRUG
72934-4360
SKNV
2024-2
CICLOPIROX OLAMINE; TERBINAFINE HYDROCHLORIDE; FLUCONAZOLE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
8 g/100 mL; 1 g/100 mL; 1 g/100 mL
72934-4360-9
201034 BENZOCAINE 20% / LIDOCAINE 8% / TETRACAINE 4%
HUMAN COMPOUNDED DRUG
72934-5405
SKNV
2024-2
LIDOCAINE; TETRACAINE; BENZOCAINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
8 g/100 mL; 4 g/100 mL; 20 g/100 mL
72934-5405-4
351031 SALICYLIC ACID 5% / SULFACETAMIDE SODIUM MONOHYDRATE 10%
HUMAN COMPOUNDED DRUG
72934-8428
SKNV
2024-1
SALICYLIC ACID; SULFACETAMIDE SODIUM
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 g/100 mL; 10 g/100 mL
72934-8428-6
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3